Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 2,369 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Completed Phase 3 Interventional Results available

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

NCT00083915
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cisplatin, Cyclophosphamide, Adriamycin, Etoposide, Melphalan, Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

NCT01134510
View directory record Official record
Conditions
Kidney Transplantation
Interventions
C1 Esterase Inhibitor, Placebos
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 17, 2026, 7:23 AM EDT
Active, not recruiting Not applicable Interventional

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

NCT04667585
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
De-escalated radiation dose, Standard radiation dose, 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)
Radiation · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department

NCT00867789
View directory record Official record
Conditions
Abscess
Interventions
Trimethoprim-sulfamethoxazole, Sugar pill
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 17, 2026, 7:23 AM EDT
Terminated Phase 3 Interventional

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

NCT01111682
View directory record Official record
Conditions
Traumatic Brain Injury, Elevated Intracranial Pressure
Interventions
Mannitol, Hypertonic Saline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 17, 2026, 7:23 AM EDT
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

NCT05462132
View directory record Official record
Conditions
Homocystinuria
Interventions
SYNB1353
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Not applicable Interventional Results available

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

NCT02764359
View directory record Official record
Conditions
Infection, Sepsis, Obesity
Interventions
IV vancomycin
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Active, not recruiting Not applicable Interventional

Prebiotic Treatment in People With Schizophrenia

NCT05527210
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Prebiotic, Placebo Prebiotic
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

NCT01667679
View directory record Official record
Conditions
Migraine, Headaches
Interventions
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

Effect of High Monounsaturated Fat Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes

NCT00622960
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
High-MUFA diet, High-CHO diet
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
30 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2008 · Synced Oct 17, 2026, 7:23 AM EDT
Not yet recruiting Not applicable Interventional

Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT06786260
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Interventional Diet
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Suspended Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07181382
View directory record Official record
Conditions
Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Fresno, California • Albuquerque, New Mexico • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 3 Interventional

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Drug · Other
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Strawberry Supplementation on Memory and Gait Among Over-weight Older Adults

NCT03162913
View directory record Official record
Conditions
Aging, Age-related Cognitive Decline, Obesity
Interventions
Strawberry, Placebo
Dietary Supplement · Other
Lead sponsor
USDA Human Nutrition Research Center on Aging
Federal
Eligibility
55 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Early Phase 1 Interventional

Effects of Glucocorticoids on Cognition in HIV-infected Women

NCT03237689
View directory record Official record
Conditions
Hiv
Interventions
Hydrocortisone, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 17, 2026, 7:23 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB

NCT07818759
View directory record Official record
Conditions
Sanfilippo Syndrome (MPS III)
Interventions
rAAV9-CMV-hNAGLUop
Biological
Lead sponsor
NeuroGT
Industry
Eligibility
6 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

NCT07417891
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis, Mild Cognitive Impairment, MCI, Mild Cognitive Impairment (MCI), Dementia
Interventions
Well-formulated ketogenic diet
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
55 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 7:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

NCT04755062
View directory record Official record
Conditions
Obesity, Blood Glucose, High
Interventions
Micronutrient-dense plant-rich Intervention
Behavioral
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026
View directory record Official record
Conditions
Intraepithelial Prostatic Neoplasia, Prostatic Neoplasms
Interventions
Lycopene 30mg, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 17, 2026, 7:23 AM EDT
Not listed Not applicable Interventional

Implementation and Evaluation of an Evidence-Based, Multilevel Lifestyle Intervention for Underserved and Rural Populations in South Texas

NCT06433258
View directory record Official record
Conditions
Cancer Prevention
Interventions
Enhanced TSSC curriculum, Original TSSC curriculum
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

NCT02691325
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Not applicable Interventional Results available

Utilizing Protein During Weight Loss to Impact Physical Function and Bone

NCT03819478
View directory record Official record
Conditions
Obesity, Weight Loss, Diet Modification, Aging, Weight Change, Body, Dietary Habits, Osteopenia, Osteoporosis, Bone Loss, Fractures, Bone
Interventions
Weight loss intervention months 0-6, Exercise intervention months 0-6, NutraBio™ CarboMax Supplement, 6-month NutraBio™ 100% Whey Protein Isolate Supplement, 18-month NutraBio™ 100% Whey Protein Isolate Supplement
Behavioral · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 17, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Results available

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

NCT05656040
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Edgewater, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 17, 2026, 7:23 AM EDT